Potential Coronavirus Vaccine Completed and Shipped For Further Testing
As the coronavirus outbreak continues to spread, an experimental vaccine to combat the disease is on its way to the top health officials.
The biotech company Moderna Inc., located in Cambridge, announced that it has shipped the first batch of vaccination for early-stage testing.
The vaccine vials are sent to the National Institute of Allergy and Infectious Diseases in Bethesda after being manufactured at a facility in Norwood.
The company announced the hopeful news through its Twitter account.
We just announced that we have shipped vials of mRNA-1273, the Company’s vaccine against the novel coronavirus, to the NIH to be used in the planned Phase 1 study in the U.S. https://t.co/jNarQEkGhr pic.twitter.com/o7EoaYeQH1— Moderna (@moderna_tx) February 24, 2020
The US government researchers will launch the first human tests of whether the experimental shot could help suppress the Wuhan epidemic, originated in China.
Scientists from all around the world are racing to find a vaccine for the coronavirus, and time will show whether the new vaccine prevails or not.
It is expected for the institute to start clinical trials by the end of April. If a successful trial occurs, it will be followed by in-depth studies and regulations. It is probable that the vaccine might not be ready for distribution until at least next year.
Currently, there are 79,773 cases of coronavirus infections, with 40,305 in mild condition, and 11,567 in critical condition. With 2,629 people deceased, and 25,272 recovered, this new vaccine might be the beam of hope for many people globally.
You can stay up to date through Latest Updates on Wuhan's Deadly Virus.
mRNA biotechnology stands to revolutionize healthcare by giving clinicians the power to direct our bodies to make the specific proteins we need.